Bobak Azamian, M.D., Ph.D., has been the driving force behind Tarsus Pharmaceuticals since its inception. With a strong background in medicine and business, he co-founded the company and became its CEO in 2018. Before this, he led Metavention, Inc., focusing...

Bobak Azamian, M.D., Ph.D., has been the driving force behind Tarsus Pharmaceuticals since its inception. With a strong background in medicine and business, he co-founded the company and became its CEO in 2018. Before this, he led Metavention, Inc., focusing on developing treatments for diabetes and metabolic diseases. He also played a key role in Vibrato Medical, creating wearable devices for vascular conditions. Bobak has a solid academic foundation, holding a Bachelor's in Biophysics from Rice University, a Ph.D. in Chemistry from the University of Oxford, and an M.D. from Harvard Medical School. Under his leadership, Tarsus has made significant strides in the biotechnology industry. He also chairs the board, ensuring that technical innovation aligns with business goals. In 2023, he earned a compensation of $632,700, which is heavily tied to Tarsus’s performance, reflecting a structure aimed at driving success for the company and its shareholders. His insider trading track record showcases confidence in his company, with stock holdings peaking around $51.88 million in early 2021. This suggests a deep commitment to Tarsus and belief in its future.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Tarsus Pharmaceuticals, Inc. CEOs

T

Bobak Azamian

CEO of Tarsus Pharmaceuticals, Inc.

Education

M.D. and Ph.D. from the University of California, San Diego

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1974 - 51 years ago

CEO of Tarsus Pharmaceuticals, Inc. for

4 years 7 months (Nov 2020 - Present)

Previous Experience

Chief Executive Officer of Tarsus Pharmaceuticals, Inc.

Rivals

Competitors/colleagues of Bobak Azamian

Holdings

See how much did Bobak Azamian make over time.

Bobak Azamian's financial journey with Tarsus Pharmaceuticals is notable. His stock holdings reached a staggering $51.88 million in January 2021, indicating a strong belief in the company’s potential. Since then, his wealth in Tarsus stock has fluctuated. By 2023, it...

Bobak Azamian's financial journey with Tarsus Pharmaceuticals is notable. His stock holdings reached a staggering $51.88 million in January 2021, indicating a strong belief in the company’s potential. Since then, his wealth in Tarsus stock has fluctuated. By 2023, it saw ups and downs, ending the year around $16 million. These fluctuations tell a story of a volatile market and a CEO closely tied to the company’s performance. His extensive stock ownership suggests not just financial investment, but also personal commitment, having held as much as 9% of Tarsus’s total stock. This commitment reflects his long-term vision for the company he helped to create.

Loading...

Total Stock Sold

$9.25M

TARS

$9.25M

448,248 TARS shares

What if they kept their stock?

If Bobak Azamian didn't sell their stock, today they would have:
Extra TARS448,248 shares worth $9.22M.
This is -0.25% and $23.52K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Bobak Azamian.

TARS

$300.00K

TARS at $50.00/share

Mar 24, 2025

Sale

TARS

$1.16M

TARS at $47.93/share

Mar 18, 2025

Sale

TARS

$318.70K

TARS at $30.60/share

Mar 15, 2024

Sale

TARS

$161.76K

TARS at $20.22/share

Dec 27, 2023

Sale

TARS

$806.40K

TARS at $20.16/share

Dec 20, 2023

Sale

TARS

$148.88K

TARS at $18.61/share

Nov 15, 2023

Sale

TARS

$105.92K

TARS at $13.24/share

Oct 18, 2023

Sale

TARS

$137.68K

TARS at $17.21/share

Sep 20, 2023

Sale

TARS

$137.84K

TARS at $17.23/share

Aug 23, 2023

Sale

TARS

$2.04M

TARS at $19.66/share

Jul 19, 2023

Sale

Compensation History

See how much did Bobak Azamian make over time.

In 2023, Bobak Azamian received a total compensation of $632,700, primarily from his salary, which was $619,500. There were no bonuses, stock grants, or options awarded this year, emphasizing a performance-linked compensation structure. This framework is designed to attract and retain top talent while aligning Bobak's incentives with the success of Tarsus Pharmaceuticals. His compensation reflects the company’s performance metrics linked to product development and clinical studies. Over recent years, Bobak's earnings have varied, with significant bonuses in previous years reflecting his contributions to the company’s growth. In a way, his earnings reflect Tarsus's journey, indicating a CEO who is as invested in the company’s future as he is in his own.

Year

2023

Total Compensation

$632.70K

Salary

$619.50K

Board Justification

The compensation philosophy aligns with company performance and aims to attract and retain top talent while linking compensation to individual and corporate performance metrics.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2023.

Other

$13.20K

Board Justification

This includes $13,200 in matching contributions for the 401(k) plan.

Restricted Stock

$0.00(0 Common Stock)

Board Justification

No stock awards vested in 2023.

Performance Metrics

Performance metrics for determining compensation include corporate and individual performance goals related to product development and advancement of clinical studies.

Other Tarsus Pharmaceuticals, Inc. CEOs

Here are other CEOs of Tarsus Pharmaceuticals, Inc.

Michael Ackermann

Ex-CEO of Tarsus Pharmaceuticals, Inc.

September 2019 - November 2020